EP1530973A3 - Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat - Google Patents

Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat Download PDF

Info

Publication number: EP1530973A3
Authority: EP; European Patent Office
Prior art keywords: cell; tissue; antagonist; allogeneic; methods
Prior art date: 1994-04-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP05075209A

Other languages

English (en)

French (fr)

Other versions

EP1530973A2 (de

Inventor

Randolph J. Dartmouth Medical School Noelle

Fiona H. Durie

David C. Oregon Health & Science Univ. Parker

Michael C. Appel

Nancy E. Phillips

John P. Mordes

Dale L. Grenier

Aldo A. Rossini

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Dartmouth College

University of Massachusetts Medical Center

Original Assignee

Dartmouth College

University of Massachusetts Medical Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-25

Filing date

1995-04-25

Publication date

2006-12-27

1995-04-25 Application filed by Dartmouth College, University of Massachusetts Medical Center filed Critical Dartmouth College

2005-05-18 Publication of EP1530973A2 publication Critical patent/EP1530973A2/de

2006-12-27 Publication of EP1530973A3 publication Critical patent/EP1530973A3/de

Status Withdrawn legal-status Critical Current

Links

210000001744 T-lymphocyte Anatomy 0.000 title abstract 5
238000000034 method Methods 0.000 title abstract 5
210000000056 organ Anatomy 0.000 title abstract 3
230000001939 inductive effect Effects 0.000 title abstract 2
210000004027 cell Anatomy 0.000 abstract 5
102100032937 CD40 ligand Human genes 0.000 abstract 4
101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 abstract 4
101000868215 Homo sapiens CD40 ligand Proteins 0.000 abstract 4
230000000735 allogeneic effect Effects 0.000 abstract 4
239000005557 antagonist Substances 0.000 abstract 4
210000001519 tissue Anatomy 0.000 abstract 3
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
210000003719 b-lymphocyte Anatomy 0.000 abstract 2
230000001419 dependent effect Effects 0.000 abstract 2
239000012636 effector Substances 0.000 abstract 2
239000003446 ligand Substances 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 1
210000002216 heart Anatomy 0.000 abstract 1
230000003993 interaction Effects 0.000 abstract 1
210000000936 intestine Anatomy 0.000 abstract 1
210000004153 islets of langerhan Anatomy 0.000 abstract 1
210000003734 kidney Anatomy 0.000 abstract 1
210000004185 liver Anatomy 0.000 abstract 1
210000004072 lung Anatomy 0.000 abstract 1
210000003205 muscle Anatomy 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
230000000284 resting effect Effects 0.000 abstract 1
210000003491 skin Anatomy 0.000 abstract 1
210000002784 stomach Anatomy 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Microbiology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Transplantation (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Obesity (AREA)
Toxicology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)

EP05075209A 1994-04-25 1995-04-25 Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat Withdrawn EP1530973A3 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/234,987 US5683693A (en)	1994-04-25	1994-04-25	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US234987		1994-04-25
EP95917593A EP0757557B1 (de)	1994-04-25	1995-04-25	Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
EP95917593A Division EP0757557B1 (de)	1994-04-25	1995-04-25	Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat

Publications (2)

Publication Number	Publication Date
EP1530973A2 EP1530973A2 (de)	2005-05-18
EP1530973A3 true EP1530973A3 (de)	2006-12-27

Family

ID=22883593

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP05075209A Withdrawn EP1530973A3 (de)	1994-04-25	1995-04-25	Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat
EP95917593A Expired - Lifetime EP0757557B1 (de)	1994-04-25	1995-04-25	Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP95917593A Expired - Lifetime EP0757557B1 (de)	1994-04-25	1995-04-25	Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat

Country Status (34)

Country	Link
US (4)	US5683693A (de)
EP (2)	EP1530973A3 (de)
JP (1)	JP2974415B2 (de)
KR (1)	KR100468330B1 (de)
CN (1)	CN1134266C (de)
AP (1)	AP764A (de)
AT (1)	ATE288281T1 (de)
AU (1)	AU710925B2 (de)
BG (1)	BG62121B1 (de)
BR (1)	BR9507509A (de)
CA (1)	CA2188672A1 (de)
CZ (1)	CZ291266B6 (de)
DE (1)	DE69533984T2 (de)
DK (1)	DK0757557T3 (de)
EE (1)	EE03516B1 (de)
ES (1)	ES2237757T3 (de)
FI (1)	FI118792B (de)
GE (1)	GEP20022648B (de)
HU (1)	HU221752B1 (de)
IS (1)	IS2118B (de)
LT (1)	LT4309B (de)
LV (1)	LV11785B (de)
MD (1)	MD1444B2 (de)
NO (2)	NO319787B1 (de)
NZ (1)	NZ284905A (de)
OA (1)	OA10591A (de)
PL (1)	PL180031B1 (de)
PT (1)	PT757557E (de)
RO (1)	RO114743B1 (de)
RU (1)	RU2169009C2 (de)
SI (1)	SI9520057A (de)
SK (1)	SK136996A3 (de)
UA (1)	UA44892C2 (de)
WO (1)	WO1995028957A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7070777B1 (en) *	1991-11-15	2006-07-04	The Trustees Of Columbia University In The City Of New York	Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) *	1991-11-15	1995-12-12	The Trustees Of Columbia University In The City Of New York	Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en)	1992-02-14	2002-10-29	Bristol-Myers Squibb Company	CD40 receptor ligands
ZA946765B (en) *	1993-09-02	1996-02-15	Dartmouth College	Methods of prolonged suppression of humoral immunity
EP0721469B1 (de) *	1993-09-02	2000-01-05	Trustees of Dartmouth College	Anti-gp39 antikoerper und deren verwendungen
US5683693A (en)	1994-04-25	1997-11-04	Trustees Of Dartmouth College	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) *	1995-01-26	1999-03-02	Bristol-Myers Squibb Company	Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6440418B1 (en) *	1995-11-07	2002-08-27	Idec Pharmaceuticals Corporation	Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) *	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en)	1995-12-01	2002-01-22	The Trustees Of Columbia University In The City Of New York	Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
DK0892643T4 (da) *	1996-03-20	2009-12-14	Bristol Myers Squibb Co	Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
IL130785A0 (en) *	1997-01-10	2001-01-28	Biogen Inc	Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same
EP1754490A3 (de) *	1997-06-20	2010-01-20	Biogen Idec MA Inc.	CD154-Blockadetherapie der Pankreasinselzellentransplantation bei Primaten
CN1195546C (zh) *	1997-06-20	2005-04-06	拜奥根有限公司	结合cd154的单克隆抗体抑制产生胰岛素的组织移植物的排斥的用途
US20050031611A1 (en) *	1998-05-08	2005-02-10	Beth Israel Deaconess Medical Center	Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
DK1100515T3 (da) *	1998-07-30	2005-12-12	Univ Minnesota	Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister
US20020199218A1 (en) *	1999-08-19	2002-12-26	Daphne Goring	Proline-rich extensin-like receptor kinases
RU2162297C1 (ru) *	1999-11-25	2001-01-27	Камакин Владислав Владимирович	Способ индивидуального подбора оптимального питания человека
WO2001079555A2 (en)	2000-04-14	2001-10-25	Millennium Pharmaceuticals, Inc.	Roles of jak/stat family members in tolerance induction
CA2408691A1 (en)	2000-05-12	2001-11-22	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods for achieving immune suppression
EP1289554A4 (de) *	2000-06-02	2004-05-26	Univ Minnesota	Immunotherapeutische methode zur vermeidung der abstossung von inselzellen
CA2410188A1 (en) *	2000-06-06	2001-12-13	Idec Pharmaceutical Corporation	Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
US20040022787A1 (en)	2000-07-03	2004-02-05	Robert Cohen	Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CN1318086C (zh)	2000-07-03	2007-05-30	布里斯托尔-迈尔斯斯奎布公司	可溶性ctla4分子用于制备治疗风湿性疾病的药物组合物中的用途
CA2364983A1 (en) *	2000-12-13	2002-06-13	John R. Coleman	Nucleic acid molecules and polypeptides for catabolism of abscisic acid
WO2002078743A1 (en) *	2001-02-16	2002-10-10	University Of Rochester	Compositions and methods for reducing tranfusion reactions
US7597895B2 (en) *	2001-02-20	2009-10-06	The Governing Council Of The University Of Toronto	Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en)	2001-02-20	2009-07-07	Kane Biotech, Inc.	Signal peptides, nucleic acid molecules and methods for treatment of caries
MXPA03010568A (es)	2001-05-23	2005-03-07	Squibb Bristol Myers Co	Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
ATE328906T1 (de) *	2002-06-28	2006-06-15	Domantis Ltd	Dual-specifische liganden mit erhöhter halbwertszeit
WO2005006949A2 (en) *	2003-07-07	2005-01-27	Wagner David H	Methods for predicting development of auto-immune diseases and treatment of same
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1795587A1 (de) *	2005-12-07	2007-06-13	Schuler, Gerold, Prof. Dr.	Methode zur direkten Kultivierung von dendritischen Zellen ohne Zentrifugationsschritt
WO2007103134A2 (en) *	2006-03-02	2007-09-13	Alexion Pharmaceuticals, Inc.	Prolongation of survival of an allograft by inhibiting complement activity
FR2934140B1 (fr) *	2008-07-25	2010-09-03	Seb Sa	Couvercle d'appareil electromenager de cuisson comportant un sous-ensemble de filtration
EP2445932B1 (de)	2009-06-26	2018-02-28	Soricimed Biopharma Inc.	Soriciden-abgeleitete peptide und verfahren zum nachweisen von trpv-6-krebsarten und medikamentenverabreichung
WO2013013708A1 (en)	2011-07-26	2013-01-31	Fundació Institut D'investigació Biomèdica De Bellvitge	Treatment of acute rejection in renal transplant
CN107249318A (zh)	2014-12-10	2017-10-13	明尼苏达大学董事会	用于治疗疾病的遗传修饰的细胞、组织和器官
RU2580640C1 (ru) *	2014-12-25	2016-04-10	Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации	Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
RU2688172C1 (ru) *	2018-04-05	2019-05-20	Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского)	Способ профилактики отторжения трансплантата трупной почки

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993008207A1 (en) *	1991-10-25	1993-04-29	Immunex Corporation	Novel cytokine
EP0555880A2 (de) *	1992-02-14	1993-08-18	Bristol-Myers Squibb Company	CD40CR-Rezeptor und Liganden dafür
EP0583799A1 (de) *	1989-05-23	1994-02-23	Otsuka Pharmaceutical Co., Ltd.	Monoklonale Antikörper gegen das auf der Oberfläche der aktivierten endothelialen Zellen antigenischen Sialoglykoprotein
WO1994004570A1 (en) *	1992-08-21	1994-03-03	Schering Corporation	Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0595659A2 (de) *	1992-10-30	1994-05-04	Bristol-Myers Squibb Company	Rezeptorliganden von der extrazellularen Matrix, die die Leukozytenfunktion modulieren
WO1995006666A1 (en) *	1993-09-02	1995-03-09	Trustees Of Dartmouth College	Anti-gp39 antibodies and uses therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5690933A (en) *	1989-05-31	1997-11-25	Glaxo Wellcome Inc.	Monoclonal antibodies for inducing tolerance
US5474771A (en) *	1991-11-15	1995-12-12	The Trustees Of Columbia University In The City Of New York	Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5540926A (en) *	1992-09-04	1996-07-30	Bristol-Myers Squibb Company	Soluble and its use in B cell stimulation
US5597563A (en) *	1992-09-04	1997-01-28	Beschorner; William E.	Method induction of antigen-specific immune tolerance
ZA946765B (en) *	1993-09-02	1996-02-15	Dartmouth College	Methods of prolonged suppression of humoral immunity
US5869049A (en) *	1993-09-02	1999-02-09	Trustees Of Dartmouth College	Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US5683693A (en)	1994-04-25	1997-11-04	Trustees Of Dartmouth College	Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

1994
- 1994-04-25 US US08/234,987 patent/US5683693A/en not_active Expired - Lifetime
1995
- 1995-04-25 EE EE9600162A patent/EE03516B1/xx not_active IP Right Cessation
- 1995-04-25 ES ES95917593T patent/ES2237757T3/es not_active Expired - Lifetime
- 1995-04-25 CZ CZ19963125A patent/CZ291266B6/cs unknown
- 1995-04-25 MD MD97-0009A patent/MD1444B2/ro unknown
- 1995-04-25 AP APAP/P/1996/000906A patent/AP764A/en active
- 1995-04-25 SI SI9520057A patent/SI9520057A/sl unknown
- 1995-04-25 CA CA002188672A patent/CA2188672A1/en not_active Abandoned
- 1995-04-25 GE GEAP19953439A patent/GEP20022648B/en unknown
- 1995-04-25 NZ NZ284905A patent/NZ284905A/en not_active IP Right Cessation
- 1995-04-25 PT PT95917593T patent/PT757557E/pt unknown
- 1995-04-25 KR KR1019960705968A patent/KR100468330B1/ko not_active IP Right Cessation
- 1995-04-25 JP JP7527745A patent/JP2974415B2/ja not_active Expired - Fee Related
- 1995-04-25 SK SK1369-96A patent/SK136996A3/sk unknown
- 1995-04-25 RO RO96-02051A patent/RO114743B1/ro unknown
- 1995-04-25 DK DK95917593T patent/DK0757557T3/da active
- 1995-04-25 WO PCT/US1995/004832 patent/WO1995028957A2/en active IP Right Grant
- 1995-04-25 PL PL95317022A patent/PL180031B1/pl unknown
- 1995-04-25 CN CNB951935623A patent/CN1134266C/zh not_active Expired - Fee Related
- 1995-04-25 EP EP05075209A patent/EP1530973A3/de not_active Withdrawn
- 1995-04-25 DE DE69533984T patent/DE69533984T2/de not_active Expired - Fee Related
- 1995-04-25 EP EP95917593A patent/EP0757557B1/de not_active Expired - Lifetime
- 1995-04-25 BR BR9507509A patent/BR9507509A/pt not_active Application Discontinuation
- 1995-04-25 AT AT95917593T patent/ATE288281T1/de not_active IP Right Cessation
- 1995-04-25 AU AU23585/95A patent/AU710925B2/en not_active Ceased
- 1995-04-25 UA UA96114392A patent/UA44892C2/uk unknown
- 1995-04-25 HU HU9602924A patent/HU221752B1/hu not_active IP Right Cessation
- 1995-04-25 RU RU96122475/14A patent/RU2169009C2/ru not_active IP Right Cessation
1996
- 1996-10-18 NO NO19964440A patent/NO319787B1/no unknown
- 1996-10-22 IS IS4378A patent/IS2118B/is unknown
- 1996-10-23 FI FI964272A patent/FI118792B/fi active
- 1996-10-24 OA OA60909A patent/OA10591A/en unknown
- 1996-11-19 BG BG100991A patent/BG62121B1/bg unknown
- 1996-11-25 LT LT96-165A patent/LT4309B/lt not_active IP Right Cessation
- 1996-11-25 LV LVP-96-440A patent/LV11785B/en unknown
1997
- 1997-08-05 US US08/906,332 patent/US5902585A/en not_active Expired - Lifetime
1999
- 1999-01-05 US US09/227,081 patent/US6375950B1/en not_active Expired - Lifetime
2004
- 2004-10-07 US US10/962,033 patent/US7501124B2/en not_active Expired - Fee Related
2005
- 2005-03-04 NO NO20051182A patent/NO20051182L/no not_active Application Discontinuation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0583799A1 (de) *	1989-05-23	1994-02-23	Otsuka Pharmaceutical Co., Ltd.	Monoklonale Antikörper gegen das auf der Oberfläche der aktivierten endothelialen Zellen antigenischen Sialoglykoprotein
WO1993008207A1 (en) *	1991-10-25	1993-04-29	Immunex Corporation	Novel cytokine
EP0555880A2 (de) *	1992-02-14	1993-08-18	Bristol-Myers Squibb Company	CD40CR-Rezeptor und Liganden dafür
WO1994004570A1 (en) *	1992-08-21	1994-03-03	Schering Corporation	Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0595659A2 (de) *	1992-10-30	1994-05-04	Bristol-Myers Squibb Company	Rezeptorliganden von der extrazellularen Matrix, die die Leukozytenfunktion modulieren
WO1995006666A1 (en) *	1993-09-02	1995-03-09	Trustees Of Dartmouth College	Anti-gp39 antibodies and uses therefor
WO1995006481A1 (en) *	1993-09-02	1995-03-09	Trustees Of Dartmouth College	Methods for inducing antigen-specific t cell tolerance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DURIE, F. ET AL.: "Allogeneic Tolerance induced by Treatment with an Antibody to the Ligand for CD40", FASEB JOURNAL, ABSTRACTS, PART I, vol. 8, no. 4, 15 March 1994 (1994-03-15), pages a477, XP008068753 *
DURIE, F. ET AL.: "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune disease", RES. IMMUNOL., vol. 145, no. 3, March 1994 (1994-03-01), pages 200 - 205, XP000579835 *
DURIE, F. ET AL.: "The Role of CD40 in the Regulation of Humoral and Cell-mediated Immunity", IMMUNOL. TODAY, (ELSEVIER SCIENCE LTD), vol. 15, no. 9, pages 406 - 411, XP002398357 *
FOY, M. ET AL.: "The Expansive Role of CD40 and its Ligand, gp39, in Immunity", SEMIN. IMMUNOL., vol. 6, no. 5, 31 October 1994 (1994-10-31), pages 259 - 266, XP002405170 *

Also Published As

Publication number	Publication date
HU9602924D0 (en)	1996-12-30
SK136996A3 (en)	1999-01-11
ES2237757T3 (es)	2005-08-01
FI964272A0 (fi)	1996-10-23
EE03516B1 (et)	2001-10-15
IS4378A (is)	1996-10-22
CN1150760A (zh)	1997-05-28
EP0757557B1 (de)	2005-02-02
BG100991A (en)	1998-01-30
HU221752B1 (hu)	2002-12-28
FI118792B (fi)	2008-03-31
PL317022A1 (en)	1997-03-03
EP0757557A1 (de)	1997-02-12
MD1444B2 (ro)	2000-04-30
BR9507509A (pt)	1997-02-02
DE69533984D1 (de)	2005-03-10
CN1134266C (zh)	2004-01-14
GEP20022648B (en)	2002-03-25
NO20051182L (no)	1996-12-23
SI9520057A (sl)	1998-06-30
FI964272A (fi)	1996-12-19
RO114743B1 (ro)	1999-07-30
BG62121B1 (bg)	1999-03-31
JPH09512271A (ja)	1997-12-09
EE9600162A (et)	1997-06-16
LV11785A (lv)	1997-06-20
US5902585A (en)	1999-05-11
US6375950B1 (en)	2002-04-23
JP2974415B2 (ja)	1999-11-10
WO1995028957A3 (en)	1995-11-23
EP1530973A2 (de)	2005-05-18
IS2118B (is)	2006-06-15
US20050152897A1 (en)	2005-07-14
US5683693A (en)	1997-11-04
PT757557E (pt)	2005-05-31
HUT76091A (en)	1997-06-30
WO1995028957A2 (en)	1995-11-02
ATE288281T1 (de)	2005-02-15
AP9600906A0 (en)	1997-01-31
LT96165A (en)	1997-11-25
MD970009A (en)	1999-01-31
LT4309B (lt)	1998-03-25
LV11785B (en)	1998-02-20
US7501124B2 (en)	2009-03-10
NZ284905A (en)	2004-10-29
NO964440D0 (no)	1996-10-18
OA10591A (en)	2002-07-15
UA44892C2 (uk)	2002-03-15
DE69533984T2 (de)	2006-04-27
KR100468330B1 (ko)	2005-12-30
AU710925B2 (en)	1999-09-30
CZ312596A3 (en)	1997-03-12
NO319787B1 (no)	2005-09-12
AP764A (en)	1999-09-16
PL180031B1 (pl)	2000-12-29
CZ291266B6 (cs)	2003-01-15
AU2358595A (en)	1995-11-16
RU2169009C2 (ru)	2001-06-20
DK0757557T3 (da)	2005-05-23
CA2188672A1 (en)	1995-11-02
NO964440L (no)	1996-12-23

Legal Events

Date	Code	Title	Description
2005-04-01	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2005-05-18	17P	Request for examination filed	Effective date: 20050127
2005-05-18	AC	Divisional application: reference to earlier application	Ref document number: 0757557 Country of ref document: EP Kind code of ref document: P
2005-05-18	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
2005-07-20	RIN1	Information on inventor provided before grant (corrected)	Inventor name: ROSSINI, ALDO A. Inventor name: NOELLE, RANDOLPH J. Inventor name: MORDES, JOHN P. Inventor name: PARKER, DAVID C. Inventor name: APPEL, MICHAEL C. Inventor name: PHILLIPS, NANCY E. Inventor name: DURIE, FIONA H. Inventor name: GRENIER, DALE L.
2005-10-26	RIN1	Information on inventor provided before grant (corrected)	Inventor name: PARKER, DAVID C.,OREGON HEALTH & SCIENCE UNIV. Inventor name: MORDES, JOHN P. Inventor name: NOELLE, RANDOLPH J.,DARTMOUTH MEDICAL SCHOOL Inventor name: DURIE, FIONA H. Inventor name: PHILLIPS, NANCY E. Inventor name: GRENIER, DALE L. Inventor name: ROSSINI, ALDO A. Inventor name: APPEL, MICHAEL C.
2005-11-23	RIN1	Information on inventor provided before grant (corrected)	Inventor name: DURIE, FIONA H. Inventor name: APPEL, MICHAEL C. Inventor name: MORDES, JOHN P. Inventor name: ROSSINI, ALDO A. Inventor name: PARKER, DAVID C.,OREGON HEALTH & SCIENCE UNIV. Inventor name: GRENIER, DALE L. Inventor name: NOELLE, RANDOLPH J.,DARTMOUTH MEDICAL SCHOOL Inventor name: PHILLIPS, NANCY E.
2006-10-13	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2006-11-15	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
2006-11-17	PUAF	Information related to the publication of a search report (a3 document) modified or deleted	Free format text: ORIGINAL CODE: 0009199SEPU
2006-11-24	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2006-12-20	D17D	Deferred search report published (deleted)
2006-12-27	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
2007-08-08	17Q	First examination report despatched	Effective date: 20070703
2007-09-05	AKX	Designation fees paid	Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
2009-01-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2009-02-18	18D	Application deemed to be withdrawn	Effective date: 20080815

Publication	Publication Date	Title
EP1530973A3 (de)	2006-12-27	Verfahren zur Anregung von T-Zelltoleranz zu einem Gewebe- oder Organtransplantat
RU96122475A (ru)	1999-01-20	Способы индуцирования т-клеточной толерантности к тканевому или органному трансплантанту
Shevach	1985	The effects of cyclosporin A on the immune system.
Skuk et al.	1999	Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in the host muscle
US8916147B2 (en)	2014-12-23	Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
CA2387542A1 (en)	2001-05-10	Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
JP2002506831A5 (de)	2010-05-13
WO1996012794A3 (en)	1996-09-12	Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
WO1998020932A3 (en)	1999-10-21	Conditioning for allogeneic stem cell transplantation
Gurevitch et al.	1999	TRANSPLANTATION OF ALLOGENEIC OR XENOGENEIC BONE MARROW WITHIN THE DONOR STROMAL MICROENVIRONMENT1
CA2284079A1 (en)	1998-09-11	Immunotoxins and methods of inducing immune tolerance
Prigozhina et al.	1997	PERMANENT AND SPECIFIC TRANSPLANTATION TOLERANCE INDUCED BY A NONMYELOABLATIVE TREATMENT TO A WIDE VARIETY OF ALLOGENEIC TISSUES: I. Induction of Tolerance by a Short Course of Total Lymphoid Irradiation and Selective Elimination of the Donor-Specific Host Lymphocytes: 1
CA2272130A1 (en)	1998-06-04	Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
Lubaroff et al.	1970	The abolition of tolerance of skin homografts in rats with isoantiserum
Yamasaki et al.	1998	Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts
Kobayashi et al.	1995	Migration of donor cells into the thymus is not essential for induction and maintenance of systemic tolerance after liver transplantation in the rat.
Ajiki et al.	2003	Generation of donor hematolymphoid cells after rat-limb composite grafting
MX9605051A (es)	1998-02-28	Metodos para inducir la tolerancia de celulas t a un injerto u organo.
Rao et al.	1996	The two-way paradigm of transplantation immunology
DE69527640T2 (de)	2003-04-24	Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten
CA2218166A1 (en)	1996-10-17	Methods of inducing immune tolerance using immunotoxins
WO1996032137B1 (en)	1997-02-20	Methods of inducing immune tolerance using immunotoxins
Achauer et al.	1985	Immunosurgery
WO2001000679A3 (en)	2002-01-24	Methods for inducing t cell non-responsiveness to a tissue or organ graft
Tsuchida et al.	2002	Vascularized bone-marrow allotransplantation in rats prolongs the survival of simultaneously grafted alloskin